

Gerd K Rosenkranz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6401239/publications.pdf>

Version: 2024-02-01

32
papers

543
citations

687363

13
h-index

677142

22
g-index

33
all docs

33
docs citations

33
times ranked

758
citing authors

#	ARTICLE	IF	CITATIONS
1	Replicability of studies following a dual-criterion design. <i>Statistics in Medicine</i> , 2021, 40, 4068-4076.	1.6	2
2	Methods for the analysis of multiple endpoints in small populations: A review. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 1-29.	0.8	32
3	Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSP/PSI working group on subgroup analysis. <i>Pharmaceutical Statistics</i> , 2019, 18, 126-139.	1.3	11
4	Empirical Bayes estimators in hierarchical models with mixture priors. <i>Journal of Applied Statistics</i> , 2018, 45, 2958-2980.	1.3	1
5	Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. <i>Scientific Reports</i> , 2018, 8, 16970.	3.3	33
6	Applicability and added value of novel methods to improve drug development in rare diseases. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 200.	2.7	12
7	Subgroup identification in clinical trials via the predicted individual treatment effect. <i>PLoS ONE</i> , 2018, 13, e0205971.	2.5	26
8	Estimands and Their Role in Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2017, 9, 268-271.	0.8	45
9	Estimands—new statistical principle or the emperor's new clothes?. <i>Pharmaceutical Statistics</i> , 2017, 16, 4-5.	1.3	3
10	Exploratory subgroup analysis in clinical trials by model selection. <i>Biometrical Journal</i> , 2016, 58, 1217-1228.	1.0	20
11	Remarks on designs enriching for placebo non-responders. <i>Clinical Trials</i> , 2016, 13, 338-343.	1.6	10
12	Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. <i>Journal of Neurodevelopmental Disorders</i> , 2016, 8, 1.	3.1	69
13	Bayesian Design of Proof-of-Concept Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 155-162.	1.6	42
14	Analysis of cross-over studies with missing data. <i>Statistical Methods in Medical Research</i> , 2015, 24, 420-433.	1.5	16
15	Bootstrap corrections of treatment effect estimates following selection. <i>Computational Statistics and Data Analysis</i> , 2014, 69, 220-227.	1.2	14
16	Missing Data in Noninferiority Trials. <i>Statistics in Biopharmaceutical Research</i> , 2013, 5, 383-393.	0.8	10
17	Analysis Sets and Inference in Clinical Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2013, 47, 455-459.	1.6	7
18	Joint Modeling of Outcome, Observation Time, and Missingness. <i>Journal of Biopharmaceutical Statistics</i> , 2011, 21, 252-262.	0.8	5

#	ARTICLE	IF	CITATIONS
19	The impact of randomization on the analysis of clinical trials. <i>Statistics in Medicine</i> , 2011, 30, 3475-3487.	1.6	20
20	Another view on the analysis of cardiovascular morbidity/mortality trials. <i>Pharmaceutical Statistics</i> , 2011, 10, 196-202.	1.3	1
21	A note on the Hodges-Lehmann estimator. <i>Pharmaceutical Statistics</i> , 2010, 9, 162-167.	1.3	26
22	An Approach to Integrated Safety Analyses from Clinical Studies. <i>Drug Information Journal</i> , 2010, 44, 649-657.	0.5	6
23	Modeling laboratory data from clinical trials. <i>Computational Statistics and Data Analysis</i> , 2009, 53, 812-819.	1.2	7
24	Analysis of Adverse Events in the Presence of Discontinuations. <i>Drug Information Journal</i> , 2006, 40, 79-87.	0.5	6
25	A Note on Ethnic Sensitivity Studies. <i>Journal of Biopharmaceutical Statistics</i> , 2006, 16, 15-23.	0.8	4
26	Is It Possible to Claim Efficacy if One of Two Trials is Significant While the other Just Shows a Trend?. <i>Drug Information Journal</i> , 2002, 36, 875-879.	0.5	12
27	Can we reduce the dose of a vaccine?. <i>Contemporary Clinical Trials</i> , 1997, 18, 43-53.	1.9	7
28	Diffusion approximation of controlled branching processes with random environments. <i>Stochastic Analysis and Applications</i> , 1985, 3, 363-377.	1.5	7
29	Growth models with stochastic differential equations. an example from tumor immunology. <i>Mathematical Biosciences</i> , 1985, 75, 175-186.	1.9	9
30	On global stability of discrete population models. <i>Mathematical Biosciences</i> , 1983, 64, 227-231.	1.9	30
31	On the persistence of tumor initiation in two-stage carcinogenesis on mouse skin. <i>Carcinogenesis</i> , 1983, 4, 771-775.	2.8	45
32	APL-Programs for the analysis of carcinogenicity experiments. <i>Computer Programs in Biomedicine</i> , 1982, 15, 87-91.	0.7	5